Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Comparison of the Inflammatory Response in Patients Undergoing Surgery for Degenerative Spinal Diseases: Sevoflurane-Based Balanced Anesthesia Versus Target-Controlled Propofol Infusion (TCI)

8. november 2026 oppdatert av: Mateo Peric, University Clinical Hospital Mostar

Comparison of the Inflammatory Response of the Organism After Surgical Treatment of Degenerative Spina Diseases Under Balanced Anesthesia and Target Controlled Infusion Anesthesia

A prospective cohort study with patients undergoing surgery at the Neurosurgery Clinic of the University Clinical Hospital Mostar.

Inclusion/Exclusion Criteria: Inclusion criteria will be: a) patients over 18 years of age undergoing elective surgery for degenerative spine diseases b) ASA status 1-3 Exclusion criteria will be: a) emergency surgeries b) spinal trauma c) allergy to any of the drugs routinely administered during surgery (cefazolin, pantoprazole, metoclopramide, sevoflurane, propofol, fentanyl) d) patients under 18 years of age e) ASA status 4 Variables and Data Sources: General patient data will be collected (gender, age, height, weight), comorbidities, and baseline values for hemoglobin, hematocrit, leukocytes, C-reactive protein (CRP), interleukin 6 (IL-6), ferritin, blood glucose (BG), creatine kinase, myoglobin, and cholesterol. These values will be monitored on the first and second postoperative days, and the dynamics of the results will be recorded. Intraoperatively, the need for vasopressors and transfusions will be documented, and the occurrence of postoperative infections, as well as postoperative nausea and vomiting, will be monitored.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Patients undergoing surgical treatment for degenerative spinal disease will be randomly assigned to two groups.

The first group will receive balanced anesthesia. Anesthesia will be induced using propofol, fentanyl, and a neuromuscular blocking agent, most commonly atracurium, while hypnosis will be maintained using an inhaled mixture of sevoflurane, oxygen, and air.

The second group will receive total intravenous anesthesia (TIVA). Anesthesia will be induced in the same manner as in the first group, while hypnosis during surgery will be maintained by a continuous infusion of propofol, adjusted according to the target plasma concentration of propofol (target-controlled infusion anesthesia - TCI anesthesia), with an oxygen-air mixture.

All patients will have their comorbidities documented, with particular emphasis on obesity, arterial hypertension, hypercholesterolemia, and diabetes mellitus. Their American Society of Anesthesiologists (ASA) physical status classification will also be recorded.

Patients' sex, body weight, and height will be recorded, and their body mass index (BMI) will be calculated.

Before transfer to the operating room, all participants will receive premedication with midazolam at a dose of 0.02-0.04 mg/kg. Antibiotic prophylaxis with a first-generation cephalosporin will be administered and repeated every three hours.

Preoperative baseline levels of hemoglobin, hematocrit, leukocytes, C-reactive protein (CRP), interleukin-6 (IL-6), ferritin, blood glucose, creatine kinase (CK), myoglobin, and cholesterol will be measured. The same laboratory parameters will be assessed on the first and second postoperative days, and changes in their values over time will be recorded. Intraoperative blood glucose levels will also be monitored.

The need for blood product transfusion will be documented.

The depth of anesthesia will be monitored intraoperatively using entropy monitoring, and anesthetic doses will be adjusted to maintain entropy values between 40 and 60.

An arterial catheter will be inserted in all patients for invasive arterial blood pressure monitoring. Blood pressure will be maintained within 30% of the initial recorded value. Hypotension will be treated with ephedrine and/or norepinephrine. The administration of these medications will be documented and compared between the two groups.

Normal saline and other balanced crystalloid solutions will be used for intraoperative fluid replacement.

Before the end of surgery, all patients will receive analgesics for postoperative pain management. Antiemetic medications will also be administered, and the incidence of postoperative nausea and vomiting will be recorded.

Pain levels will be assessed before and after surgery. The duration of anesthesia will be documented. Pain intensity will be measured using the Visual Analog Scale (VAS).

The incidence of postoperative surgical site infections will also be monitored.

**Exclusion criteria** will include patients under 18 years of age, emergency surgical procedures, surgery for malignant diseases, and patients with contraindications to cephalosporins or any of the anesthetic agents used in the study.

The planned duration of the study is one to two years.

All surgical procedures will be performed in the neurosurgical operating room of the University Clinical Hospital Mostar. Intraoperative computed tomography (CT) with navigation will be used to ensure more precise placement of spinal implants.

Studietype

Intervensjonell

Registrering (Antatt)

100

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • patients over 18 years of age undergoing elective surgery for degenerative spine diseases
  • ASA status 1-3

Exclusion Criteria:

  • emergency surgeries
  • spinal trauma
  • allergy to any of the drugs routinely administered during surgery (cefazolin, pantoprazole, metoclopramide, sevoflurane, propofol, fentanyl)
  • patients under 18 years of age
  • ASA status 4
  • patients with imunosupressive therapy

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Sevoflurane-Based Balanced Anesthesia

Patients undergoing surgery for degenerative spinal diseases will receive balanced general anesthesia maintained with sevoflurane. The perioperative inflammatory response will be assessed using inflammatory biomarkers.

General anesthesia maintained with inhaled sevoflurane as part of a balanced anesthesia technique during surgery for degenerative spinal diseases.

Eksperimentell: Propofol-Based Total Intravenous Anesthesia (TCI)

Patients undergoing surgery for degenerative spinal diseases will receive total intravenous anesthesia maintained with propofol administered using target-controlled infusion (TCI). The perioperative inflammatory response will be assessed using inflammatory biomarkers.

General anesthesia maintained with intravenous propofol administered using target-controlled infusion (TCI) during surgery for degenerative spinal diseases.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Serum Interleukin-6 (IL-6) Concentration
Tidsramme: Before anesthesia induction (baseline), 4 hours and 24 hours after completion of surgery.

Change in serum IL-6 concentration from baseline will be compared between patients receiving sevoflurane-based balanced anesthesia and propofol-based total intravenous anesthesia (TCI). IL-6 concentrations will be measured using an ELISA assay.

Before anesthesia induction (baseline), 4 hours and 24 hours after completion of surgery.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. juni 2028

Studiet fullført (Antatt)

1. juli 2028

Datoer for studieregistrering

Først innsendt

8. november 2026

Først innsendt som oppfylte QC-kriteriene

8. november 2026

Først lagt ut (Faktiske)

13. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • eticko 224/25

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .